Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)
Read time: 2 mins
Last updated:1st Oct 2012
Primary Sponsor: Novartis Pharmaceuticals
The purpose of this study is to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
|Study start date||2012-10-01|
|Estimated primary completion date||2016-10-01|